DXCM Quote, Financials, Valuation and Earnings

Edwards Lifesciences has a net margin of 13.62% compared to DexCom's net margin of 27.83%. DexCom's return on equity of 26.6% beat Edwards Lifesciences's return on equity of 50.81%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 43.99%. On the other hand Edwards Lifesciences has an analysts' consensus of $80.42 which suggests that it could grow by 16.07%. Given that DexCom has higher upside potential than Edwards Lifesciences, analysts believe DexCom is more attractive than Edwards Lifesciences.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.123, suggesting its more volatile than the S&P 500 by 12.315%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are smaller than Edwards Lifesciences quarterly revenues of $1.4B. DexCom's net income of $151.7M is lower than Edwards Lifesciences's net income of $385.6M. Notably, DexCom's price-to-earnings ratio is 49.43x while Edwards Lifesciences's PE ratio is 9.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.23x versus 7.25x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 13.62% compared to DexCom's net margin of -117.16%. DexCom's return on equity of 26.6% beat Moderna's return on equity of -29.09%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 43.99%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than DexCom, analysts believe Moderna is more attractive than DexCom.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Moderna quarterly revenues of $956M. DexCom's net income of $151.7M is higher than Moderna's net income of -$1.1B. Notably, DexCom's price-to-earnings ratio is 49.43x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.23x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 13.62% compared to DexCom's net margin of 16.85%. DexCom's return on equity of 26.6% beat Insulet's return on equity of 43.11%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 43.99%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 22.95%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Insulet quarterly revenues of $597.5M. DexCom's net income of $151.7M is higher than Insulet's net income of $100.7M. Notably, DexCom's price-to-earnings ratio is 49.43x while Insulet's PE ratio is 44.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.23x versus 9.11x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 13.62% compared to DexCom's net margin of 0.27%. DexCom's return on equity of 26.6% beat Tandem Diabetes Care's return on equity of -37.18%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 43.99%. On the other hand Tandem Diabetes Care has an analysts' consensus of $41.65 which suggests that it could grow by 117.27%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.446, suggesting its more volatile than the S&P 500 by 44.616%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Tandem Diabetes Care quarterly revenues of $282.6M. DexCom's net income of $151.7M is higher than Tandem Diabetes Care's net income of $755K. Notably, DexCom's price-to-earnings ratio is 49.43x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.23x versus 1.33x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.